急性缺血性脑卒中的损伤机制及临床治疗的研究进展
摘要
们的身心健康和生活质量造成了极大的影响。本文主要阐述了急性缺血性脑卒中后的损伤机制及临床治疗的最新进展，为
临床治疗提供参考。
关键词
全文:
PDF参考
[1] Campbell BCV, Khatri P, 2020. Stroke. Lancet Lond.
Engl. 396, 129–142. 10.1016/S0140-6736(20)31179-X.
[2] Zille M, et al. , 2022. Novel targets, treatments, and
advanced models for intracerebral haemorrhage. eBioMedicine 76.
10.1016/j.ebiom.2022.103880.
[3] Bonkhoff AK, et al. , 2021. Outcome after acute ischemic
stroke is linked to sex-specific lesion patterns. Nat. Commun. 12,
3289. 10.1038/s41467-021-23492-3 [DOI] [PMC free article]
[PubMed] [Google Scholar].
[4] Boehme AK, Esenwa C, Elkind MS, 2017. Stroke Risk
Factors, Genetics, and Prevention. Circ Res 120, 472–495.
[5] Balch MHH, Nimjee SM, Rink C, Hannawi Y. Beyond the
brain: The systemic pathophysiological response to acute ischemic
stroke. J Stroke. 2020;22:159–172.
[6] Moskowitz M.A., Lo E.H., Iadecola C. The science
of stroke: Mechanisms in search of treatments. Neuron.
2010;67:181–198.
[7] Orrenius S., Zhivotovsky B., Nicotera P. Regulation of
cell death: The calcium–apoptosis link. Nat. Rev. Mol. Cell Biol.
2003;4:552–565.
[8] Won S.J., Kim J.-E., Cittolin-Santos G.F., Swanson
R.A. Assessment at the Single-Cell Level Identifies Neuronal
Glutathione Depletion as Both a Cause and Effect of Ischemia-
Reperfusion Oxidative Stress. J. Neurosci. 2015;35:7143–7152.
[9] Mishra M., Hedna V.S. Neuroinflammation after acute
ischemic stroke: A volcano hard to contain. Chin. J. Contemp.
Neurol. Neurosurg. 2013;13:964.
[10] Tuttolomondo A., Maida C., Pinto A. Inflammation
and Inflammatory Cell Recruitment in Acute Cerebrovascular
Diseases. Curr. Immunol. Rev. 2015;11:24–32.
[11] Davalos D., Grutzendler J., Yang G., Kim J.V., Zuo Y.,
Jung S., Littman D.R., Dustin M.L., Gan W.-B. ATP mediates
rapid microglial response to local brain injury in vivo. Nat.
Neurosci. 2005;8:752–758.
[12] Geissmann F., Gordon S., Hume D.A., Mowat A.,
Randolph G.J. Unravelling mononuclear phagocyte heterogeneity.
Nat. Rev. Immunol. 2010;10:453–460.
[13] Mayer A., Clifford J.A., Aldulescu M., Frenkel J.A.,
Holland M.A., Hall M.L., Glaser K.B., Berry J. Cyanobacterial
Microcystis aeruginosa Lipopolysaccharide Elicits Release of
Superoxide Anion, Thromboxane B2, Cytokines, Chemokines,
and Matrix Metalloproteinase-9 by Rat Microglia. Toxicol. Sci.
2011;121:63–72.
[14] Fisher M. Characterizing the target of acute stroke
therapy. Stroke. 1997;28:866–872.
[15] Murray V, Norrving B, Sandercock PA, Terént A,
Wardlaw JM, Wester P. The molecular basis of thrombolysis and
its clinical application in stroke. J Intern Med. 2010;267:191–
208. doi: 10.1111/j.1365-2796.2009.02205.x.
[16] Emberson J, Lees KR, Lyden P, et al. . Effect of
treatment delay, age, and stroke severity on the effects of
intravenous thrombolysis with alteplase for acute ischaemic stroke:
a meta-analysis of individual patient data from randomised trials.
Lancet 2014; 384: 1929–1935.
[17] Berge E, Whiteley W, Audebert H, et al. . European
Stroke Organisation (ESO) guidelines on intravenous thrombolysis
for acute ischaemic stroke. Eur Stroke J 2021; 6: I–LXII.
[18] Ahmed N， Wahlgren N， Grond M， Hennerici M，
Lees KR， Mikulik R， Parsons M， Roine RO， Toni D. 急性
中风后 3-4.5 小时阿替普酶溶栓的实施和结果：SITS-ISTR
的最新分析。柳叶刀神经学 2010;9:866–874.
[19] Saver JL, Gornbein J, Grotta J, Liebeskind D, Lutsep
H, Schwamm L, Scott P, Starkman S. Number needed to treat to
benefit and to harm for intravenous tissue plasminogen activator
therapy in the 3- to 4.5-h window: Joint outcome table analysis of
the ECASS 3 trial. Stroke. 2009;40:2433–2437.
[20] Schwamm LH, Ali SF, Reeves MJ, Smith EE, Saver JL,
Messe S, Bhatt DL, Grau-Sepulveda MV, Peterson ED, Fonarow
GC. Temporal trends in patient characteristics and treatment with
intravenous thrombolysis among acute ischemic stroke patients at
Get With The Guidelines-Stroke hospitals. Circ Cardiovasc Qual
Outcomes. 2013;6:543–549.
[21] Ingall TJ, O’Fallon WM, Asplund K, Goldfrank LR,
Hertzberg VS, Louis TA, Christianson TJH. Findings from the
reanalysis of the NINDS tissue plasminogen activator for acute
ischemic stroke treatment trial. Stroke. 2004;35:2418–2424.
[22] Jansen O, von Kummer R, Forsting M, Hacke W, Sartor
K. Thrombolytic therapy in acute occlusion of the intracranial
internal carotid artery bifurcation. AJNR Am J Neuroradiol.
1995;16:1977–1986.
[23] Mandavia R, Qureshi MI, Dharmarajah B, Head K,
Davies AH. Safety of carotid intervention following thrombolysis in
acute ischaemic stroke. Eur J Vasc Endovasc Surg. 2014;48:505–
512. doi: 10.1016/j.ejvs.2014.08.012.
[24] Rha JH, Saver JL. The impact of recanalization
o n i s c h e m i c s t r o k e o u t c o m e : a m e t a - a n a l y s i s [ J ] .
Stroke,2007,38(3):967-973.
[25] Mandavia R, Qureshi MI, Dharmarajah B, Head K,
Davies AH. Safety of carotid intervention following thrombolysis in
acute ischaemic stroke. Eur J Vasc Endovasc Surg. 2014;48:505–
512.
[26] Furlan AJ, Abou-Chebl A. The role of recombinant pro-
urokinase (r-pro-UK) and intra-arterial thrombolysis in acute
ischaemic stroke: The PROACT trials. Prolyse in acute cerebral
thromboembolism. Curr Med Res Opin. 2002;18(Suppl 2):S44–
S47. doi: 10.1185/030079902125000723.
[27] Hao C, Ding W, Xu X, Sun Q, Li X, Wang W, Zhao
Z, Tang L. Effect of recombinant human prourokinase on
thrombolysis in a rabbit model of thromboembolic stroke. Biomed
Rep. 2018;8:77–84.
[28] 李粉根 , 刘大军等 . 超选择性动脉溶栓联合支架
取栓治疗急性大 脑中动脉闭塞 [J]. 中国微侵袭神经外科杂
志 ,2018,23(5):215-218.
[29] 中国卒中学会，中国卒中学会神经介入分会，中
华预防医学会卒 中预防与控制专业委员会介入学组 . 急
性缺血性卒中血管内治疗 中国指南 2018[J]. 中国卒中杂
志 ,2018,13(7):706-729.
[30] Agrawal A, Golovoy D, Nimjee S, Ferrell A, Smith T,
Britz G. Mechanical thrombectomy devices for endovascular
management of acute ischemic stroke: Duke stroke center
experience. Asian J Neurosurg. 2012;7:166–170.
[31] Deng L, Qiu S, Wang L, Li Y, Wang D, Liu M.
Comparison of four food and drug administration-approved
mechanical thrombectomy devices for acute ischemic stroke: A
network meta-analysis. World Neurosurg. 2019;127:e49–e57.
[32] Nogueira RG, Lutsep HL, Gupta R, Jovin TG, Albers
GW, Walker GA, Liebeskind DS, Smith WS. TREVO 2 Trialists:
Trevo versus Merci retrievers for thrombectomy revascularisation
of large vessel occlusions in acute ischaemic stroke (TREVO 2): A
randomised trial. Lancet. 2012;380:1231–1240.
[33] Suzuki K, Matsumaru Y, Takeuchi M, Morimoto M,
Kanazawa R, Takayama Y, Kamiya Y, Shigeta K, Okubo S,
Hayakawa M, et al. Effect of mechanical thrombectomy without
vs with intravenous thrombolysis on functional outcome among
patients with acute ischemic stroke: The SKIP randomized clinical
trial. JAMA. 2021;325:244–253.
[34] Machado M, Alves M, Fior A, Fragata I, Papoila
AL, Reis J, Nunes AP. Functional outcome after mechanical
thrombectomy with or without previous thrombolysis. J Stroke
Cerebrovasc Dis. 2021;30:105495.
[35] BHATIA V，JAIN C，RAY S，et al.Mechanical
Thrombec⁃ tomy in embolic cardiac myxoma：case report and
literature review[J]. Neurol India，2021，69（3）：707-710.
[36] Naqvi IA, Kamal AK, Rehman H. Multiple versus fewer
antiplatelet agents for preventing early recurrence after ischaemic
stroke or transient ischaemic attack. Cochrane Database Syst Rev.
2020;8(8):CD009716.
[37] Shaban A, Monlezun DJ, Rincon N, Tiu J, Valmoria M,
Martin-Schild S. Safety and efficacy of acute clopidogrel load in
patients with moderate and severe ischemic strokes. Stroke Res
Treat. 2016;2016:8915764. doi: 10.1155/2016/8915764.
[38] Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et
al. (2013). CHANCE Investigators. Clopidogrel with aspirin in
acute minor stroke or transient ischemic attack. N Engl J Med,
369:11-9.
[39] Wang Y, Wang Y, Zhao X, et al. ; CHANCE
Investigators. Clopidogrel with aspirin in acute minor stroke or
transient ischemic attack. N Engl J Med. 2013; 369:11–19.
[40] Johnston SC, Easton JD, Farrant M, Barsan W, Conwit
RA, Elm JJ, et al. (2018). Clinical Research Collaboration,
Neurological Emergencies Treatment Trials Network, and the
POINT Investigators. Clopidogrel and Aspirin in Acute Ischemic
Stroke and High-Risk TIA. N Engl J Med, 379:215-225.
[41] Davignon J. Beneficial cardiovascular pleiotropic effects
of statins. Circulation. 2004; 109:III39–III43.
[42] Amarenco P, Bogousslavsky J, Callahan A, III, et al. ;
Stroke Prevention by Aggressive Reduction in Cholesterol Levels
(SPARCL) Investigators. High-dose atorvastatin after stroke or
transient ischemic attack. N Engl J Med. 2006; 355:549–559.
[43] Amarenco P, Kim JS, Labreuche J, et al. ; Treat Stroke to
Target Investigators. A comparison of two LDL cholesterol targets
after ischemic stroke. N Engl J Med. 2020; 382:9.
[44] Manktelow BN, Potter JF. Interventions in the
management of serum lipids for preventing stroke recurrence.
Cochrane Database Syst Rev. 2009; 2009:CD002091.
[45] McKinney JS, Kostis WJ. Statin therapy and the risk
of intracerebral hemorrhage: A meta-analysis of 31 randomized
controlled trials. Stroke. 2012; 43:2149–2156.
[46] Chrostek, et al. , 2019. Efficacy of stem cell-based
therapies for stroke. Brain Res. 1722, 146362. 10.1016/
j.brainres.2019.146362.
[47] Hoang DM, et al. , 2022. Stem cell-based therapy
for human diseases. Signal Transduct. Target. Ther. 7, 1–41.
10.1038/s41392-022-01134-4.
[48] Chrostek, et al. , 2019. Efficacy of stem cell-based
therapies for stroke. Brain Res. 1722, 146362. 10.1016/
j.brainres.2019.146362.
[49] Krakauer JW, Carmichael ST, Corbett D, et al. Getting
neurorehabilitation right: What can be learned from animal
models?. Neurorehabil Neural Repair. 2012; 26:923–931
[50] Hu MH, Hsu SS, Yip PK, et al. Early and intensive
rehabilitation predicts good functional outcomes in patients
admitted to the stroke intensive care unit. Disabil Rehabil. 2010;
32:1251–1259.
[51] Langhorne P, Wu O, Rodgers H, et al. A Very
Early Rehabilitation Trial after stroke (AVERT): A phase III,
multicentre, randomised controlled trial. Health Technol Assess.
2017; 21:1–120.
(4 摘要 Views, 29 PDF Downloads)
Refbacks
- 当前没有refback。